With a lack of contract manufacturing organizations (CMOs) operating in the cell and...
- Lack of CMO availability threatens cell and gene therapy development
- CD47-targeted therapies: the breast cancer mop?
- Through CRISPR gene editing we can change the nature of our species
- Could groundbreaking gene therapies offer a breakthrough to retinal disease sufferers?
- Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
Lack of CMO availability threatens cell and gene therapy development
With a lack of contract manufacturing organizations (CMOs) operating in the cell and gene therapies sphere, it appears to be heading towards major capacity crunches in both R&D and commercial manufacturing.
Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis
Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.
Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence
Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence.
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progresssion with Yervoy (ipilimumab).
Through CRISPR gene editing we can change the nature of our species
In 2018, we can expect to see large numbers of CRISPR trials taking off all over the world and we should not be afraid of this technology, because we severely need it if we want to cure chronic disease or change our nature to better cope with a changing environment and new challenges for our species.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.